Table 4 Comparison of patients with persistent hematuria and patients without hematuria

 Sex (male/female)

31/49

27/37

0.68

 Age (years)

57.2 ± 12.3

58.8 ± 14.5

0.50

 Hypertension (n %)

20/25.0

23/35.9

0.15

 Cardiovascular disease (n %)

11/13.8

8/12.5

0.83

 Diabetes (n %)

10/12.5

13/20.3

0.20

 Using ACEI/ARB (n %)

18/22.5

11/17.2

0.43

 ANCA subtypes (PR3/MPO)

11/69

4/60

0.14

 ANCA level (RU/mL)

187.0(96.0,200.0)

142.0(88.0,200.0)

0.14

 BVAS

19.1 ± 6.9

19.0 ± 7.0

0.96

 Hemoglobin (g/L)

97.5 ± 21.2

98.7 ± 19.6

0.76

 Leukocyte (×10⁹/L)

8.5 ± 2.9

9.2 ± 2.7

0.19

 Neutrophil (×10⁹/L)

6.4 ± 2.9

6.8 ± 2.5

0.41

 Platelets (×10⁹/L)

259.4 ± 102.3

271.8 ± 108.0

0.53

 ESR (mm/1 h)

56.5(43.5,79.8)

85.0(45.5,110.0)

0.009

 C-reactive protein (mg/L)

9.8(3.5,39.2)

18.4(8.7,62.6)

0.043

 Urine protein excretion (g/24 h)

1.0(0.3,1.8)

0.9(0.6,1.7)

0.62

 Serum creatinine (μmol/L)

167.5 (111.5,341.0)

163.0(110.1,329.8)

0.10

 eGFR (mL/min/1.73m²)

39.2 ± 28.9

39.2 ± 29.1

0.10

 Fever (n/%)

31/38.8

23/35.9

0.73

 Fatigue (n/%)

36/45.0

34/53.1

0.33

 Rash (n/%)

10/12.5

9/14.1

0.64

 Weight loss (n/%)

31/38.8

33/51.6

0.12

 Muscle pain (n/%)

13/16.3

15/23.4

0.28

 Arthralgia (n/%)

15/18.8

9/14.1

0.78

 Lung (n/%)

49/61.3

35/54.7

0.47

 ENT (n/%)

37/46.3

29/45.3

0.91

 Gastrointestinal tract (n/%)

23/28.8

15/23.4

0.47

 Nervous system (n/%)

7/8.8

11/17.2

0.13

 Prednisone-equivalent dose (g)

8.9 ± 4.0

9.7 ± 3.2

0.23

 Oral CTX/IV CTX

8/72

7/57

0.65

 Serum creatinine (μmol/L)

115.5(96.5,145.0)

122.0(95.3,160.3)

0.43

 eGFR (mL/min/1.73m²)

54.1 ± 21.16

51.1 ± 22.5

0.42

 ANCA level (RU/mL)

42.5(0.0,81.8)

0.0(0.0,37.4)

0.003

 ESR (mm/1 h)

20.0(11.0,33.0)

19.0(15.0,34.0)

0.51

 C-reactive protein (mg/L)

3.0(1.0,8.0)

3.0(1.0,5.8)

0.52

 Proteinuria (n/%)^b

48(61.5%)

22(34.4%)

0.001

 IV CTX every 3 mo/AZA/MMF

25/53/2

17/42/5

0.45

 The slope of eGFR decline (mL/min/1.73 m²/y)

3.6(1.2,7.2)

0.2(−0.2,0.8)

<0.001